Anti-Tumor Necrosis Factor (TNF) Treatments, Work Productivity and Quality of Life in Crohn's Disease (IDEA)
31 de marzo de 2017 actualizado por: AbbVie
Improvement of Work Productivity and Quality of Life With Anti-TNF Therapies Used in Crohn's Disease in Routine Clinical Practice in Turkey
This multicenter, prospective, post marketing observational study (PMOS) was designed to demonstrate long-term effects of anti-Tumor Necrosis Factor therapies on Work Productivity and Impairment scales in participants with moderate to severe Crohn's Disease (CD) under routine conditions.
Secondary objectives of this study were long-term improvement of Quality of Life (QoL), evaluation of improvement of extraintestinal symptoms and comorbidities, and evaluation of safety.
Descripción general del estudio
Estado
Terminado
Condiciones
Descripción detallada
Male or female participants between 18 - 65 years of age with moderate to severe CD for whom the treating physician had recently initiated an anti-TNF treatment were included in this study.
Anti-TNF treatments were administered according to the treating physician's decision and applicable product label in Turkey.
No interventions were made to the treatment and the participant discontinuance or to the follow-up decisions of the treating physician.
Enrolled participants were observed for one year.
Tipo de estudio
De observación
Inscripción (Actual)
106
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años a 65 años (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Método de muestreo
Muestra no probabilística
Población de estudio
Participants with Crohn's Disease who at the time of study entry were receiving anti-Tumor Necrosis Factor treatment as prescribed in accordance with Turkish Ministry of Health regulations and reimbursement conditions
Descripción
Inclusion Criteria:
- Male or female participants between 18-65 years of age with moderately to severely (Crohn's Disease Activity Index 220-450) active Crohn's Disease with or without fistula formation
- Participants who were able to provide authorization to use and disclose information related to the study
- Proven diagnosis of Crohn's Disease in accordance with international diagnostic criteria such as European Crohn's and Colitis Organization (ECCO) guidelines
- Participants for whom the physician had initiated anti-Tumor Necrosis Factor treatment in accordance with Turkish Ministry of Health regulations and reimbursements
Exclusion Criteria:
- Participants who had a history of any kind of biological therapy and/or anti-Tumor Necrosis Factor treatments for Crohn's Disease or other indications
- Participants who had septic complications (active infection and/or active tuberculosis (TB), undrained abscess)
- Participants who had bowel obstructions and fibrotic strictures
- Participants who had received any investigational drug within 30 days prior to the Visit 1 at baseline
- For any reason, participants who were considered by the investigator to be unsuitable
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
Participants with moderate to severe Crohn's Disease
Participants for whom the treating physician had recently initiated an anti-Tumor Necrosis Factor (TNF) treatment
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Work Productivity and Activity Index (WPAI): Absenteeism
Periodo de tiempo: At baseline and 12 months
|
The Work Productivity and Activity Impairment: General Health (WPAI:GH) questionnaire was used to assess impairments in both paid work and unpaid work due to symptoms of Crohn's Disease.
The self-administered questionnaire consisted of 6 questions.
Question 2 asked participants to indicate the number of hours missed due to health problems in the past 7 days.
Question 4 asked participants to indicate the number of hours that they worked in the past 7 days.
Absenteeism (work time missed) was defined as the percentage of time absent from work due to health problems in the past week and was calculated by the formula Q2/(Q2 + Q4) × 100%.
WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
|
At baseline and 12 months
|
|
Work Productivity and Activity Index (WPAI): Presenteeism
Periodo de tiempo: At baseline and 12 months
|
The Work Productivity and Activity Impairment: General Health (WPAI:GH) questionnaire was used to assess impairments in both paid work and unpaid work due to symptoms of Crohn's Disease.
The self-administered questionnaire consisted of 6 questions.
Question 5 asked participants the degree to which their health affected productivity while working in the past 7 days, on a scale ranging from 0 to 10, with 0 indicating that health problems had no effect on their work and 10 indicating that health problems completely prevented the participant from working.
Presenteeism (impairment at work) was calculated by the formula (Q5/10) × 100%.
WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
|
At baseline and 12 months
|
|
Total Work Productivity Impairment (TWPI)
Periodo de tiempo: At baseline and 12 months
|
The Work Productivity and Activity Impairment: General Health (WPAI:GH) self-administered questionnaire was used to assess impairments in work due to symptoms of Crohn's Disease.
Q2 asked participants the number of hours missed due to health problems in the past 7 days.
Q4 asked participants the number of hours that they worked in the past 7 days.
Q5 asked participants the degree to which their health affected productivity while working in the past 7 days, on a scale ranging from 0 (health problems had no effect) to 10 (health problems completely prevented them from working).
Total work productivity impairment (TWPI) is the combined absenteeism and presenteeism for employed participants, the percentage of overall work productivity lost due to health problems.
TWPI was calculated using the formula Q2/(Q2+Q4)+[(1-(Q2/(Q2+Q4)))×(Q5/10)] × 100%.
WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
|
At baseline and 12 months
|
|
Total Activity Impairment (TAI)
Periodo de tiempo: At baseline and 12 months
|
The Work Productivity and Activity Impairment: General Health (WPAI:GH) questionnaire was used to assess impairments in both paid work and unpaid work due to symptoms of Crohn's Disease.
The self-administered questionnaire consisted of 6 questions.
Question 6 asked participants to indicate the degree to which their health affected their regular activities in the past 7 days.
Total activity impairment is the percent impairment of non-work related activities due to health problems and was calculated with the formula (Q6/10) × 100%.
WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.
|
At baseline and 12 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Short Form 36 (SF-36) Health Survey Scores
Periodo de tiempo: At baseline and 12 months
|
The Short Form 36 (SF-36) Health Survey was used to determine participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health.
Scores on each item were summed and averaged (range = 0 "worst" to 100 "best").
Increases from baseline indicate improvement.
|
At baseline and 12 months
|
|
Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Scores
Periodo de tiempo: At baseline and 12 months
|
The Inflammatory Bowel Disease Questionnaire (IBDQ) is a 32-item self-administered questionnaire to measure health-related quality of life in adults with Crohn's Disease.
The 32 items are grouped into subscales: bowel-related symptoms (10 items), systemic symptoms (5 items), social function (5 items), and emotional function (12 items).
Responses to each item within each subscale range from 1 (significant impairment) to 7 (no impairment), and mean scores ranging from 1 to 7 are calculated for each subscale.
Higher scores indicate a better quality of life.
|
At baseline and 12 months
|
|
Change in Extra-intestinal Symptoms
Periodo de tiempo: At baseline and 12 months
|
Extra-intestinal manifestations of Crohn's Disease (skeletal system [bones and muscle], dermatological [skin], hepatobiliary system [liver, gall bladder, and bile ducts], ocular [eyes] and oral [mouth]) were documented by the study investigators at each visit.
|
At baseline and 12 months
|
|
Number of Participants With Serious Adverse Events
Periodo de tiempo: From the time of informed consent until 30 days or 5 half-lives following the last dose, up to 62 weeks
|
A serious adverse event was defined as any untoward medical occurrence in a clinical investigation participant that met at least 1 of the following criteria: death, life-threatening, hospitalization or prolongation of hospitalization, congenital anomaly, persistent or significant disability/incapacity, important medical event requiring medical or surgical intervention to prevent serious outcome, elective or spontaneous abortion.
|
From the time of informed consent until 30 days or 5 half-lives following the last dose, up to 62 weeks
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Enlaces Útiles
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de mayo de 2013
Finalización primaria (Actual)
1 de febrero de 2016
Finalización del estudio (Actual)
1 de febrero de 2016
Fechas de registro del estudio
Enviado por primera vez
21 de mayo de 2013
Primero enviado que cumplió con los criterios de control de calidad
21 de mayo de 2013
Publicado por primera vez (Estimar)
23 de mayo de 2013
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
16 de junio de 2017
Última actualización enviada que cumplió con los criterios de control de calidad
31 de marzo de 2017
Última verificación
1 de marzo de 2017
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- P13-338
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
NO
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .